|
| 1） |
Diamond TH, Higano CS, Smith MR, et al. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy:recommendations for diagnosis and therapies. Cancer. 2004;100（5）:892-9. |
| 2） |
Hatano T, Igarashi H, Nakada J, et al. Bone fracture receiving LH-RH agonists for prostatic cancer. Nippon Hinyokika Gakkai Zasshi. 2000;91（6）:542-6. |
| 3） |
Diamond TH, Winters J, Smith A, et al. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade:a double blind, randomized, placebo-controlled crossover study. Cancer. 2001;92（6）:1444-50. |
| 4） |
Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001;345（13）:948-55. |
| 5） |
Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94（19）:1458-68. |
| 6） |
Dearnaley DP, Sydes MR, Mason MD, et al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer（MRC PR05 Trial）. J Natl Cancer Inst. 2003;95（17）:1300-11. |
| 7） |
Small EJ, Smith MR, Seaman JJ, et al. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol. 2003;21（23）:4277-84. |
| 8） |
Ernst DS, Tannock IF, Winquist EW, et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol. 2003;21（17）:3335-42. |
新検索ページはこちら
ログイン
お問い合わせ
書誌情報
引用文献
